However, given Sig1R's role in neurologic disorders and ChT‐induced pain [22], any in vivo study on synergistic Sig1R antagonists + Px treatment should incorporate behavioral models for Px‐induced neuropathy (such as mechanical allodynia or thermal hyperalgesia) to provide measures of pain sensitivity and other side effects. Here, SIGMAR1 is linked to nervous system disorder.